budesonide, glycopyrrolate, and formoterol fumarate

FDA Drug Profile — BREZTRI

Drug Details

Generic Name
budesonide, glycopyrrolate, and formoterol fumarate
Brand Names
BREZTRI
Application Number
NDA212122
Sponsor
AstraZeneca Pharmaceuticals LP
NDC Codes
1
Dosage Forms
AEROSOL, METERED
Routes
RESPIRATORY (INHALATION)
Active Ingredients
BUDESONIDE, FORMOTEROL, GLYCOPYRROLATE

Indications and Usage

1 INDICATIONS AND USAGE BREZTRI AEROSPHERE is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Limitations of Use: BREZTRI AEROSPHERE is not indicated for the relief of acute bronchospasm or for the treatment of asthma [see Warnings and Precautions (5.1 , 5.2) ] . BREZTRI AEROSPHERE is a combination of budesonide, an inhaled corticosteroid (ICS); glycopyrrolate, an anticholinergic; and formoterol fumarate, a long-acting beta 2 -adrenergic agonist (LABA), indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). (1) Limitations of Use: Not indicated for the relief of acute bronchospasm or for the treatment of asthma. (1 , 5.1 , 5.2)